Maruyama M, Sugino H, Akita K, Hatanaka H
Brain Res. 1987 Jan 13;401(1):14-22. doi: 10.1016/0006-8993(87)91157-7.
This paper describes the binding properties of [3H]peptidergic opioid ligands to binding sites solubilized from rat brain membranes by the treatment with 0.125% sodium glycodeoxycholate and 1 M NaCl. The highest amount of the specific binding of [3H]-[D-Ala2-, Met5]enkephalinamide was obtainable when 10-fold diluted solubilized preparations were incubated in the presence of 0.1 mM MnCl2 and 100 mM NaCl at 0 degree C (on ice) for 3 h. With this assay condition, the significant binding of following [3H]opioid ligands, which have been thought to be selective for receptor types, was also observed: [3H]-[D-Ala2, MePhe4, Gly-ol5]enkephalin (mu-type), [3H]-[D-Ala2, D-Leu5]enkephalin (delta-type) and [3H]dynorphin1-9 (kappa-type). The number of binding sites in solubilized preparations for each [3H]ligand corresponded to 40-50% recovery of original membrane-bound binding sites. The Scatchard plot of the concentration-saturation binding curve showed only one class of binding sites, with a high affinity for each [3H]ligand. Apparent dissociation constants between solubilized receptors and [3H]ligands were the same as membrane-bound ones, but the ligand specificity for each receptor-type, which was examined by binding inhibition tests with unlabeled ligands, decreased. Present results indicate that heterogeneous opioid receptors in rat brain membranes seem to be transformed into less heterogeneous forms through the treatment with glycodeoxycholate and NaCl and the dilution process.
本文描述了[3H]肽能阿片样物质配体与通过用0.125%甘氨脱氧胆酸钠和1M氯化钠处理从大鼠脑膜中溶解出来的结合位点的结合特性。当10倍稀释的溶解制剂在0.1mM氯化锰和100mM氯化钠存在下于0℃(冰上)孵育3小时时,可获得[3H]-[D-Ala2,Met5]脑啡肽酰胺的最高特异性结合量。在这种测定条件下,还观察到以下被认为对受体类型具有选择性的[3H]阿片样物质配体的显著结合:[3H]-[D-Ala2,MePhe4,Gly-ol5]脑啡肽(μ型)、[3H]-[D-Ala2,D-Leu5]脑啡肽(δ型)和[3H]强啡肽1-9(κ型)。每种[3H]配体在溶解制剂中的结合位点数相当于原始膜结合结合位点的40-50%回收率。浓度-饱和结合曲线的Scatchard图显示只有一类结合位点,对每种[3H]配体具有高亲和力。溶解受体与[3H]配体之间的表观解离常数与膜结合的相同,但通过用未标记配体进行结合抑制试验检测的每种受体类型的配体特异性降低。目前的结果表明,大鼠脑膜中的异质性阿片样物质受体似乎通过用甘氨脱氧胆酸钠和氯化钠处理以及稀释过程转化为异质性较低的形式。